Insmed Incorporated (INSM) Presents at Jefferies London Healthcare Conference 2025 Transcript

Yuxi Dong
Jefferies LLC, Research Division

Good morning, everyone. Thanks for joining the session — fireside session was Insmed and my name is Clara Dong, one of the biotech analysts here. Sitting next to me is the Chief Executive Officer of Insmed. Will Lewis, welcome.

William Lewis
President, CEO & Chairman

Thank you very much. I appreciate you having us here.

Yuxi Dong
Jefferies LLC, Research Division

Great. And it has really been a landmark year for Insmed. I have to say a first in disease FDA approval and very strong launch and impressive data in PAH and then really more to comment. I’ll pass it to you to give an audience of what’s going on at Insmed and what have kept you really busy for the past year.

William Lewis
President, CEO & Chairman

Yes. It’s been an interesting last 18 months for sure. But as we like to point out, we’re facing an even more eventful next 18 months because we’ve just had the ASPEN trial readout, which was successful, obviously, and then the approval of brensocatib for the treatment of bronchiectasis. Beyond that, we have the TPIP data that came out and then [ Uther’s ] data, which validated TPIP, its potential in IPF and PPF. So we are now looking at 3 programs at the company ARIKAYCE, which is approved for refractory MAC lung disease, conditionally in the U.S. and full approvals in Europe and Japan that is going to enjoy the ENCORE trial readout, which should expand that market opportunity from 30,000 patients to over 250,000. So that’s a big expansion should that data read out as we expect it to.